Paul Matteis analyst STIFEL

Currently out of the existing stock ratings of Paul Matteis, 167 are a BUY (66.01%), 86 are a HOLD (33.99%).

Paul Matteis

Work Performance Price Targets & Ratings Chart

Analyst Paul Matteis, currently employed at STIFEL, carries an average stock price target met ratio of 54.71% that have a potential upside of 34.39% achieved within 207 days.

Paul Matteis’s has documented 519 price targets and ratings displayed on 36 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on ALKS, Alkermes Plc at 05-Nov-2024.

Wall Street Analyst Paul Matteis

Analyst best performing recommendations are on AVDL (AVADEL PHARMACEUTICALS PLC).
The best stock recommendation documented was for AVDL (AVADEL PHARMACEUTICALS PLC) at 5/26/2022. The price target of $2 was fulfilled within 1 day with a profit of $0.93 (86.92%) receiving and performance score of 869.16.

Average potential price target upside

ACAD ACADIA Pharmaceuticals ACOR Acorda Therapeutics ALKS Alkermes Plc ALNY Alnylam Pharmaceuticals ALXN Alexion Pharmaceuticals ATHA Athira Pharma  BIIB Biogen BMRN Biomarin Pharmaceutical CERE Cerevel Therapeutics Holdings GWPH GW Pharmaceuticals plc IONS Ionis Pharmaceuticals KRTX Karuna Therapeutics NBIX Neurocrine Biosciences PRVL Prevail Therapeutics SAGE Sage Therapeutic VRTX Vertex Pharmaceuticals ZGNX Zogenix AVDL Avadel Pharmaceuticals PLC DYN Dyne Therapeutics  KALV Kalvista Pharmaceuticals GMTX Gemini Therapeutics QURE Uniqure NV ALEC Alector PRTK Paratek Pharmaceuticals ABOS Acumen Pharmaceuticals ELYM Eliem Therapeutics WVE Wave Life Sciences Ltd XENE Xenon Pharmaceuticals AKCA Akcea Therapeutics AKAO Achaogen CDTX Cidara Therapeutics DNLI Denali Therapeutics NBRV Nabriva Therapeutics AG OREX Orexigen Therapeutics PEPG PepGen Ltd GHRS GH Research PLC

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$27

$10.58 (64.43%)

$27

13 days ago
(07-Nov-2024)

8/22 (36.36%)

$9.79 (56.89%)

119

Buy

$28

$11.58 (70.52%)

$28

13 days ago
(07-Nov-2024)

0/4 (0%)

$10.79 (62.70%)

Hold

1 months 10 days ago
(10-Oct-2024)

11/14 (78.57%)

$9.98 (39.89%)

141

Buy

$23

$6.58 (40.07%)

$30

3 months 12 days ago
(08-Aug-2024)

0/3 (0%)

$7.28 (46.31%)

Buy

$20

$3.58 (21.80%)

$28

3 months 13 days ago
(07-Aug-2024)

16/21 (76.19%)

$4.83 (31.84%)

184

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Paul Matteis is most bullish on?

Potential upside of $51.74 has been obtained for ALNY (ALNYLAM PHARMACEUTICALS)

Which stock is Paul Matteis is most reserved on?

Potential downside of $7.97 has been obtained for ALKS (ALKERMES PLC)

What Year was the first public recommendation made by Paul Matteis?

On 2013

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?